MedTrace Logo

Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes

NCT02586129 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 249

Last updated 2018-10-03

No results posted yet for this study

Summary

Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes.

Conditions

Interventions

DRUG

YH14755

20/1500mg, QD

DRUG

Metformin

1500mg, QD

DRUG

Rosuvastatin

20mg, QD

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Hakcheol Jang, M.D., Ph.D. · Department of Internal Medicine, SNU Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-04
Primary Completion
2017-07-07
Completion
2017-07-07

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02586129 on ClinicalTrials.gov